Is Crohn's disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease

被引:235
作者
Greenstein, RJ
机构
[1] VAMC Bronx, Dept Surg 112, Bronx, NY 10468 USA
[2] VAMC Bronx, Lab Mol Surg Res, Bronx, NY 10468 USA
关键词
D O I
10.1016/S1473-3099(03)00724-2
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Although Crohn's disease is considered to be autoimmune in origin, there is increasing evidence that it may have an infectious cause. The most plausible candidate is Mycobacterium avium subspecies paratuberculosis (MAP). Intriguingly, Koch's postulates may have been fulfilled for MAP and Crohn's disease, even though they still have not been met for Mycobacterium leprae and leprosy. In animals MAP causes Johne's disease, a chronic wasting intestinal diarrhoeal disease evocative of Crohn's disease. Johne's disease occurs in wild and domesticated animals, including dairy herds. Viable MAP is found in human and cow milk, and is not reliably killed by standard pasteurisation. MAP is ubiquitous in the environment including in potable water. Since cell-wall-deficient MAP usually cannot be identified by Ziehl-Neelsen staining, identification of MAP in human beings requires culture or detection of MAP DNA or RNA. If infectious in origin, Crohn's disease should be curable with appropriate antibiotics. Many studies that argue against a causative role for MAP in Crohn's disease have used antibiotics that are inactive against MAP. However, trials that include macrolide antibiotics indicate that a cure for Crohn's disease is possible. The necessary length of therapy remains to be determined. Mycobacterial diseases have protean clinical manifestations, as does Crohn's disease. The necessity of stratifying Crohn's disease into two clinical manifestations (perforating and non-perforating) when interpreting the results of antibiotic therapy is discussed. Rational studies to evaluate appropriate therapies to cure Crohn's disease are proposed.
引用
收藏
页码:507 / 514
页数:8
相关论文
共 148 条
[1]  
*ADV COMM MICR SAF, 2001, MYC AV SUBSP PAR REV
[2]  
*ADV COMM MICR SAF, 2003, PREL RES NAT STUD MI
[3]  
*ADV COMM MICR SAF, 2001, HEAT RES MYC AV SUBP
[4]  
*ADV COMM MICR SAF, 2003, MYC AV SUBSP PAR CRO
[5]   CONTROLLED TRIAL OF ANTIMYCOBACTERIAL THERAPY IN CROHNS-DISEASE - CLOFAZIMINE VERSUS PLACEBO [J].
AFDHAL, NH ;
LONG, A ;
LENNON, J ;
CROWE, J ;
ODONOGHUE, DP .
DIGESTIVE DISEASES AND SCIENCES, 1991, 36 (04) :449-453
[6]   A multiplex polymerase chain reaction assay for the detection of Mycobacterium paratuberculosis DNA in Crohn's disease tissue [J].
AlShamali, M ;
Khan, I ;
AlNakib, B ;
AlHassan, F ;
Mustafa, AS .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 (08) :819-823
[7]   RESPONSE OF TUBERCULOUS STRICTURE TO ANTITUBERCULOUS TREATMENT [J].
ANAND, BS ;
NANDA, R ;
SACHDEV, GK .
GUT, 1988, 29 (01) :62-69
[8]   MYCOBACTERIUM [J].
BARKSDALE, L ;
KIM, KS .
BACTERIOLOGICAL REVIEWS, 1977, 41 (01) :217-372
[9]   Paratuberculosis infection of nonruminant wildlife in Scotland [J].
Beard, PM ;
Daniels, MJ ;
Henderson, D ;
Pirie, A ;
Rudge, K ;
Buxton, D ;
Rhind, S ;
Greig, A ;
Hutchings, MR ;
McKendrick, I ;
Stevenson, K ;
Sharp, JM .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (04) :1517-1521
[10]   Genetic susceptibility to tuberculosis in Africans: A genome-wide scan [J].
Bellamy, R ;
Beyers, N ;
McAdam, KPWJ ;
Ruwende, C ;
Gie, R ;
Samaai, P ;
Bester, D ;
Meyer, M ;
Corrah, T ;
Collin, M ;
Camidge, DR ;
Wilkinson, D ;
Hoal-van Helden, E ;
Whittle, HC ;
Amos, W ;
van Helden, P ;
Hill, AVS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) :8005-8009